title: Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer.
abstract: Heparin-induced thrombocytopenia (HIT) is a serious adverse reaction to heparin treatment with a high risk of thrombosis. Heparin must be discontinued immediately and replaced with alternative anticoagulants that do not interact with HIT antibodies. In this case, a lung cancer patient, diagnosed with HIT was successfully treated with apixaban.
authors.affiliation: Department of Clinical Biochemistry Næstved Hospital Næstved Denmark.
authors.forename: Pia Bükmann
authors.initials: PB
authors.lastname: Larsen
authors.affiliation: Department of Clinical Biochemistry Næstved Hospital Næstved Denmark.
authors.forename: Maja
authors.initials: M
authors.lastname: Jørgensen
authors.affiliation: Department of Clinical Biochemistry Næstved Hospital Næstved Denmark.
authors.forename: Lennart
authors.initials: L
authors.lastname: Friis-Hansen
authors.affiliation: Department of Clinical Oncology Næstved Hospital Næstved Denmark.
authors.forename: Steen
authors.initials: S
authors.lastname: Ingeberg
keywords: Apixaban; cancer; dalteparin; heparin‐induced thrombocytopenia